Assessments are made at baseline, post-treatment and at the 6-month follow-up.
Assessments were made at baseline, on day 2, and day 4 or 5.
Interventions: Three plethysmography studies were made: at baseline, and at three and six months of treatment.
MADRS assessments were made at baseline, Day 7, and at Day 21 or study endpoint.
These video recordings were made at baseline of the SMASH study, whereas self-reported musculoskeletal symptoms were assessed both at baseline and during a three year follow-up.
Assessments were made at baseline, day 8 and day 15 for visual skin dryness, transepidermal water loss (TEWL), hydration, desquamation, subject-perceived itch and quality of life (QoL).
Assessments of mood, symptoms of illness and temperature were made at baseline and at 1.5, 3, and 6 h post-injection.
To monitor the disease course, spirometry and DLCO assessments were made at baseline, every 4 weeks until week 24, and every 8 weeks thereafter.
Acquisitions were made at baseline (T0), immediately after (T1) and 3 hours after (T2) a single anodal tDCS session (see below).
Multiple assessments were made at baseline.
Impressions of restoration were made at baseline.
